Infection with Coxiella burnetii, the causative agent of Q fever, can result in life-threatening 25 persistent infection. Reactogenicity hinders worldwide implementation of the only licensed 26 human Q fever vaccine. We previously demonstrated long-lived immunoreactivity in individuals 27 with past symptomatic and asymptomatic Coxiella infection (convalescents) to promiscuous 28 HLA-class II C. burnetii epitopes, providing the basis for a novel T-cell-targeted subunit 29 vaccine. Here we investigated in a cohort of 22 individuals with persistent infection (chronic Q 30 fever) whether they recognize the same set of epitopes, or distinct epitopes that could be 31 candidates for a therapeutic vaccine or aid in the diagnosis of persistent infection.
Introduction
asymptomatic C. burnetii infection; these are here-after referred to as 'convalescents' since 70 infection was cleared. In these naturally exposed subjects, we demonstrated long-lived 71 immunoreactivity to promiscuous CD4 T-cell epitopes, while HLA class I epitope responses 72 were sparse in this cohort (7) . One possible explanation for the latter was that class I responses 73 might have contracted faster than class II responses, as previously observed following smallpox 74 infection or vaccination and tuberculosis treatment (8) (9) (10) (11) . In this initial study, there were no 75 striking differences between past asymptomatic or symptomatic infected individuals, all of In the present study we therefore analyzed T-cell reactivity to the same set of epitopes in a 84 cohort of subjects diagnosed and treated for persistent C. burnetii infection (chronic Q fever). 85 The aim was to investigate whether subjects with chronic Q fever (i) show potentially greater 86 reactivity to class I epitopes given their more recent exposure, (ii) recognize the same or a 87 distinct set of class II epitopes and (iii) differ in their effector memory T-cell response profile 88 compared to individuals with resolved acute symptomatic or past asymptomatic infection.
89

Results
90
Chronic Q fever subjects have cultured ELISpot response patterns to HLA class I and II C. 91 burnetii epitopes comparable to that of convalescent subjects 92 A group of 22 individuals with proven (n=16) and probable (n=6) chronic Q fever consented for 93 participation in this study (Table 1) . All but two chronic Q fever subjects still had phase I IgG 94 titers of ≥1024 at inclusion into the study (median with interquartile range: 4096 ), 95 and 13/16 proven and 1/6 probable subjects were still undergoing antibiotic treatment. For 96 analysis of T-cell epitope-specific responses in the chronic Q fever cohort, preference was given 97 to individuals with proven chronic Q fever who were diagnosed in 2016 or later and still 98 undergoing antibiotic treatment. Subjects were scheduled for blood collection based on 99 availability for class I and II peptide screening (Table 1 ). In total, 13 proven and one probable 100 chronic Q fever patients were tested for promiscuous class II epitope-specific responses ( Table   101 S1), and 10 proven and three probable chronic Q fever patients for class I epitope-specific 102 responses (Table S2 ). HLA typing of the two selected groups showed supertype distributions 103 largely comparable to expected frequencies in the general population and/or those in the 104 previously analyzed convalescent groups (Table S3 and S4), except for an underrepresentation of 105 HLA-DR11, A11 and B8 and an overrepresentation of HLA-A3 supertypes, which may be 106 partially attributed to the small group sizes.
107 108 T-cell responses were first analyzed by cultured IFN ELISpot, which both enhances detection of 109 low frequency responses and preferentially measures central memory T-cells (13) . Similar to 110 previous observations for convalescent C. burnetii-exposed subjects, 9/14 chronic Q fever 111 patients (64%) showed responses to 3-14 HLA class II peptides per donor ( Figure 1A ), while 112 responses to HLA class I peptides were rare, with only three subjects showing responses to one 113 or two peptides each ( Figure 1B) . When directly comparing the data from the chronic Q fever 114 cohort to convalescent subjects (asymptomatic, n=33; and symptomatic, n=23) Figure 2A ). Nevertheless, chronic subjects had the smallest proportion of non-responders 120 amongst the three groups ( Figure 2B ).
122
Both the overall breadth of responses and the responses to individual class II peptides largely 123 overlapped between chronic and convalescent subjects: In total, 33/50 HLA class II peptides 124 were recognized by at least 1/14 chronic subjects; comparable to the fraction (28/50) of HLA 125 class II peptides recognized by a similar proportion (at least 4/56, 7.14%) of convalescent 126 individuals. The same 22 peptides were recognized in both cohorts by at least 7% of the subjects.
127
The peptides that were not recognized by any individual in the chronic cohort included 5/6 128 peptides that were also not recognized by any convalescent subject (p11, p34, p35, p40 and p49, 129 Figure 3 ). p37+p38, CBU_0718, p45+p46, CBU_0307/outer membrane protein). Another five of these 21 138 highly antigenic peptides were recognized by 1/14 chronic subjects. Only a single peptide that 139 was highly antigenic in convalescents (p21 from CBU_1416/repressor protein C2), was not 140 recognized by any chronic subject tested; however, 5/14 chronic individuals did recognize a 141 second peptide (p2) from the same source protein.
143
Many of the class II peptide responses were at least as frequent in chronically infected subjects 144 as in convalescents, and despite the large difference in group sizes, responses to six class II 145 peptides were statistically significantly more frequent in chronic subjects (p6, p7, p16, p20, p30 146 and p47; Figure 3 ). All of these six peptides were recognized by four to five individuals (28-147 36%) within the chronic cohort, while for five of these peptides (all but p30), the frequency of 148 responses in the convalescent cohort was <10% (two to five out of 56 subjects). However, for 3/5 149 peptides to which >10% chronic subjects but <10% convalescents reacted, >10% convalescents Given that subjects treated for chronic Q fever had a more recent and prolonged exposure to C. 161 burnetii, we hypothesized that these individuals might also show a stronger effector memory T-162 cell response profile compared to individuals with resolved acute Q fever or past asymptomatic 163 infection. Indeed, the individuals with chronic Q fever enrolled in this study showed significantly 164 higher IFN secretion measured following whole blood stimulation with heat-killed whole-cell 165 C. burnetii (strain Cb02629) compared to convalescent subjects (Table 1, Figure S1A ).
166
Stimulation of freshly isolated PBMCs for direct ELISpot with whole-cell C. burnetii indicated 167 that this was at least partially due to a higher frequency of responding cells, with significantly 168 higher numbers of spot forming units and higher stimulation indices in chronic compared to 169 convalescent subjects (Figure S1B-C). Multiplex cytokine analysis of supernatants from whole 170 blood stimulation revealed that the greater ex vivo response was not just confined to IFN, but 171 also evident for IL-2 responses to whole-cell heat-killed C. burnetii ( Figure S2A ). The ratio 172 between IFNand IL-2 responses in chronic subjects did not differ from that found for 173 convalescent subjects ( Figure S2A ) IL-10 responses, in contrast, were lower in the chronic Q 174 fever cohort, and innate TNF and IL-1 responses did not differ between chronic and 175 convalescent subjects ( Figure S2B ). 196 In this study we compared the repertoire of HLA class II T-cell epitopes recognized by subjects 197 treated for persistent C. burnetii infection (chronic Q fever) with those recognized by 198 convalescent individuals (i.e. those with resolved past acute or asymptomatic infection) in our 199 previous study (7) . We find that individuals treated for chronic Q fever have effectively Our study provides validation of the highly antigenic potential of the previously identified 22 211 promiscuous HLA class II peptides and the identification of an additional five C. burnetii HLA 212 class II epitopes (p6, p7, p16, p20 and p47). These five peptides were recognized by four to five 213 individuals (28-36%) within the chronic cohort, highlighting their strong antigenic potential at 214 least during/ shortly after infection. Bearing in mind the small size of the group of chronic 215 patients evaluated, the fact that all but one of the epitopes found to be highly antigenic in 216 convalescent subjects (recognized by >10% individuals) were also recognized by at least one 217 subject in the chronic cohort further indicates that at least amongst this set of screened HLA class 218 II epitopes, there is no unique set of peptides to which responses would be absent in persistently 219 infected individuals, and that would warrant consideration for a separate therapeutic vaccine for 220 chronic Q fever patients. These results for chronic Q fever are in contrast to the observation of 221 "asymptomatic" epitopes in herpes simplex virus infection (12). The principle difference may be 222 that unlike Q fever, herpes simplex infection is always considered a persistent infection but can 223 remain asymptomatic nonetheless. Instead, the same set of promiscuous HLA class II epitopes 224 identified previously in the convalescent cohort (7) (14, (17) (18) (19) in foci of infection could be compromised in persistent infection. Therefore, 235 further research is required to clarify whether chronic Q fever patients can benefit from a 236 therapeutic vaccine, or whether a completely different approach is needed to achieve clearance in 237 this population.
Discussion
239
The results of this study indicate that the unexpected scarcity of detectable responses to the 240 predicted HLA class I epitopes in convalescent subjects (7) is not simply due to the long time-241 lapse between initial exposure and T-cell assays in our previous study, given that the chronic 242 subjects analyzed here were exposed to C. burnetii antigens until much more recently. An 243 obvious potential confounder in this chronic Q fever cohort is the fact that these subjects had 244 been diagnosed and received antibiotic treatment for various lengths of time. Heterogeneity in 245 time since diagnosis and in the duration of ongoing treatment, however, was minimized during 246 selection of individuals for epitope screening. Moreover, a previous study showed that duration 247 of antibiotic treatment following diagnosis of chronic Q fever, and whether subjects received 248 treatment or not, did not influence IFN secretion, at least not in a whole blood stimulation assay 249 using whole-cell C. burnetii (14) . Of note, CD8 responses have been shown to decline rapidly 250 following Mycobacterium tuberculosis treatment (10, 11) and we cannot exclude that this might In line with the observed higher frequency of circulating effector T-cell responding directly ex 256 vivo to C. burnetii epitopes as well as whole-cell C. burnetii in these persistently infected 257 individuals, we not only find stronger IFNresponses, but also significantly higher IL-2 258 production in chronic compared to convalescent individuals. IL-2 is mainly produced by antigen-259 specific activated CD4 T-cells shortly after T-cell receptor engagement (20) . Of note, these 260 results contrast with a previous study that found lower IL-2 secretion in response to whole-cell 261 C. burnetii and elevated IFN/IL-2 ratio in patients with chronic Q fever. This finding was 262 hypothesized to reflect increased numbers of circulating effector T-cells producing IFN and low 263 amounts of IL-2 (14). However, a simple supernatant secretion assay does not distinguish 264 whether different cytokines are produced by the same or different cell populations, and central 265 memory T-cells can also co-produce two or more cytokines including IL-2 (21). A possible 266 technical explanation for the discrepancy between the two studies in regards to IL-2 secretion 267 and IFN/IL-2 ratio is that in the previous study IL-2 responses were assessed after 48 h rather 268 than 24 h stimulation (14), which may have impacted measurement of this rapidly consumed 269 growth factor. Moreover, while individuals in both studies were recruited from the same region 270 and all were likely initially exposed during the 2007-2011 outbreak, patients for the other study One obvious question arising from this limited dataset is whether direct ex vivo responses to 279 specific epitopes such as p7, p10, and p19, which were confined to the chronic cohort, might be 280 of diagnostic value. This would require evaluation of a much larger cohort of past exposed 281 individuals and (ideally recently diagnosed) chronic Q fever cases and a separate group of 282 subjects with acute Q fever or recently recovered individuals. Only then will it be possible to 283 determine whether ex vivo responses to these epitopes correlate with persistent infection, or 284 simply with recent exposure. To be of value as a diagnostic tool, coverage of subjects would 285 have to be greater than the currently observed 23-30%. Otherwise, the assay would at best be of 286 supporting value in addition to the existing set of PCR, serology and scanning techniques to 287 localize infection. In conclusion, we herein validate and expand the characterization of a previously published set 290 of promiscuous C. burnetii-specific HLA class II T-cell epitope clusters as candidates for a novel 291 T-cell targeted subunit Q fever vaccine. We find that chronic Q fever patients have mounted a 292 central memory re-call T-cell response comparable to that of convalescent individuals. Finally, 293 we demonstrate that individuals treated for chronic Q fever mount a broader ex vivo response to 294 class II epitopes, which could be explored for diagnostic purposes. (Table 1) . At inclusion into the study, all participants treated for chronic 310 Q fever completed a medical questionnaire and donated blood for HLA typing and analysis of 311 serological and cellular responses to whole-cell C. burnetii. 312 313 C. burnetii-specific cultured ELISpot responses determined for this chronic Q fever cohort were 314 compared to previously published results (7) from past exposed individuals with a history of 315 resolved asymptomatic or symptomatic Q fever infection who recruited from the village of 316 Herpen, the Netherlands, one of the focal centers of the 2007-2010 Q fever outbreak (23, 24) .
317
Additional assays presented in the present study (direct ELISpot responses and cytokine release 318 during whole blood stimulation) were conducted using a subgroup from this cohort of 319 convalescent Q fever exposed individuals from Herpen.
321
The study was reviewed and approved by the Medical Ethical Committee Brabant (Tilburg, 322 Netherlands, NL51305.028.15) and all participants provided written informed consent. Immunology at the UMC Utrecht, the Netherlands, by Next Generation Sequencing and the 327 resulting HLA-A, HLA-B, and HLA-DRB1 alleles were assigned to supertype families as 328 described previously (7). Cellular responses were determined by whole blood IFNγ release assay (Q-detect TM IGRA), 335 using lithium-heparin anti-coagulated blood stimulated with C. burnetii antigen (heat killed 336 Cb02629, Wageningen Bioveterinay Research, lot 14VRIM014) and appropriate positive and 337 negative controls, as described previously (7). In addition to IFNγ ELISA, multiplex cytokine 338 analysis of whole blood stimulation supernatants for IFNγ, IL-2, IL-10, TNFα and IL-1β was Supplementary Table S1 ) and 65 HLA class I epitopes (Supplementary Table 2 ). As 348 described previously (7), these 115 epitopes were derived by immunoinformatic prediction using 349 the iVAX toolkit developed by EpiVax (http://epivax.com/immunogenicity-screening/ivax-web- For detection of C. burnetii-specific central memory T-cell responses and to increase sensitivity 367 for low frequency antigen-specific T-cells, ELISpot was preceded by antigen-specific T-cell 368 expansion with peptide pools (7) . Based on cell availability, a median of 41,000 cells per 369 expansion culture (interquartile range (IQR) 32,000-51,000) were plated per replicate well for 370 chronic Q fever subjects and data were analyzed as described previously using three combined 371 threshold criteria (7): Cultured ELISpot peptide re-stimulation responses were defined as positive 372 when they were (i) significantly higher than spot counts in matched negative control wells from legend. Responses for one donor were capped at SI=50 to be able to properly resolve the magnitude 8 of responses of the remaining subjects. 
